BlackRock’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $346M | Buy |
10,642,243
+62,766
| +0.6% | +$2.04M | 0.01% | 1264 |
|
|
2025
Q1 | $399M | Sell |
10,579,477
-526,592
| -5% | -$19.9M | 0.01% | 1169 |
|
|
2024
Q4 | $909M | Buy |
11,106,069
+439,632
| +4% | +$36M | 0.02% | 696 |
|
|
2024
Q3 | $1.22B | Buy |
10,666,437
+726,591
| +7% | +$83M | 0.03% | 543 |
|
|
2024
Q2 | $751M | Buy |
9,939,846
+426,839
| +4% | +$32.2M | 0.02% | 741 |
|
|
2024
Q1 | $650M | Buy |
9,513,007
+937,160
| +11% | +$64M | 0.02% | 844 |
|
|
2023
Q4 | $539M | Buy |
8,575,847
+1,154,596
| +16% | +$72.5M | 0.01% | 944 |
|
|
2023
Q3 | $378M | Buy |
7,421,251
+356,163
| +5% | +$18.2M | 0.01% | 1089 |
|
|
2023
Q2 | $353M | Buy |
7,065,088
+1,983,223
| +39% | +$99M | 0.01% | 1164 |
|
|
2023
Q1 | $190M | Sell |
5,081,865
-23,505
| -0.5% | -$881K | 0.01% | 1565 |
|
|
2022
Q4 | $245M | Buy |
5,105,370
+1,613,049
| +46% | +$77.3M | 0.01% | 1375 |
|
|
2022
Q3 | $83.8M | Buy |
3,492,321
+220,691
| +7% | +$5.3M | ﹤0.01% | 2066 |
|
|
2022
Q2 | $71.2M | Buy |
3,271,630
+385,608
| +13% | +$8.39M | ﹤0.01% | 2229 |
|
|
2022
Q1 | $69.7M | Buy |
2,886,022
+108,975
| +4% | +$2.63M | ﹤0.01% | 2339 |
|
|
2021
Q4 | $66.1M | Buy |
2,777,047
+252,402
| +10% | +$6M | ﹤0.01% | 2444 |
|
|
2021
Q3 | $64.1M | Buy |
2,524,645
+178,028
| +8% | +$4.52M | ﹤0.01% | 2472 |
|
|
2021
Q2 | $52.8M | Buy |
2,346,617
+157,889
| +7% | +$3.55M | ﹤0.01% | 2625 |
|
|
2021
Q1 | $43.2M | Buy |
2,188,728
+495,700
| +29% | +$9.79M | ﹤0.01% | 2673 |
|
|
2020
Q4 | $45M | Buy |
1,693,028
+688,500
| +69% | +$18.3M | ﹤0.01% | 2494 |
|
|
2020
Q3 | $49.6M | Buy |
1,004,528
+924,716
| +1,159% | +$45.7M | ﹤0.01% | 2260 |
|
|
2020
Q2 | $2.52M | Buy |
+79,812
| New | +$2.52M | ﹤0.01% | 3687 |
|